Biocidium Biopharmaceuticals
Biocidium is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel antibiotics, antifungals, and cancer treatments. Their mission is to address the global threat of multi-drug resistant bacteria, fungi, and certain cancers through innovative solutions and a robust IP portfolio. They focus on developing treatments for life-threatening infections and conditions, with ongoing projects targeting resistant pathogens such as MRSA, Candida auris, VRE, CRE, VRSA, and drug-resistant bacteria. Their work aims to combat the rising antimicrobial resistance crisis and improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Novel broad-spectrum antibiotic candidates (preclinical)
Preclinical small-molecule antibiotic candidates reported to show bactericidal activity against multiple multidrug-resistant pathogens, intended to address resistant Gram-positive and Gram-negative infections.
Antifungal candidates (preclinical)
Preclinical antifungal candidates targeting drug-resistant fungal species, including candidates advanced for Candida-related infections.
Topical therapeutic cream candidate (development)
Topical cream under development intended for treatment of specified melanocytic lesions and early-stage melanoma as a non-systemic therapeutic option.
Novel broad-spectrum antibiotic candidates (preclinical)
Preclinical small-molecule antibiotic candidates reported to show bactericidal activity against multiple multidrug-resistant pathogens, intended to address resistant Gram-positive and Gram-negative infections.
Antifungal candidates (preclinical)
Preclinical antifungal candidates targeting drug-resistant fungal species, including candidates advanced for Candida-related infections.
Topical therapeutic cream candidate (development)
Topical cream under development intended for treatment of specified melanocytic lesions and early-stage melanoma as a non-systemic therapeutic option.
Services
Supply and formulation of antimicrobial additives for integration into rubber and other polymer products to inhibit microbial growth and reduce mould and algae formation.
Partnerships and collaborative engagements to advance therapeutic candidates through development toward external commercialization.
Licensing of technology rights and know-how to third parties to facilitate commercialization of antimicrobial additives and related technologies.
Supply and formulation of antimicrobial additives for integration into rubber and other polymer products to inhibit microbial growth and reduce mould and algae formation.
Partnerships and collaborative engagements to advance therapeutic candidates through development toward external commercialization.
Licensing of technology rights and know-how to third parties to facilitate commercialization of antimicrobial additives and related technologies.
Expertise Areas
- Antibiotic discovery and preclinical development
- Antifungal discovery and preclinical development
- Microbiology and preclinical antimicrobial testing
- Topical dermatological therapeutics and formulation
Key Technologies
- Small-molecule medicinal chemistry
- Antifungal discovery platforms
- In vitro antimicrobial susceptibility assays
- In vivo preclinical infection models